The effects of Thalidomide on the proliferation,IL-6 and Cx43 expression of prostate cancer PC3 cells
YIN Wei-hua1 XIA Hong-mei1 LUO Xiao-jin2▲ XU Rong1 HU Xiao-xiong1
1.Department of Oncology,People′s Hospital of Yichun City in Jiangxi Province/Clinic Medicine School of Yichun university,Yichun 336000,China;
2.Department of Urinary Surgery,People′s Hospital of Yichun City in Jiangxi Province/ Clinic Medicine School of Yichun university,Yichun 336000,China
Abstract：Objective To observe the effects of Thalidomide on the proliferation and apoptosis of prostate cancer PC3 cells,as well as on the expression of the protein Cx43 and IL-6 in this cells.Methods Thalidomide with different concentrations (6.25,12.50,25.00,50.00,100.00 μg/ml)was added to PC3 cells at the logarithmic growth phase.MTT was used to detect the inhibitory effect of different concentration of Thalidomide on proliferation of PC3 cells,the apoptosis rate of PC3 cells was studied by Annexin V fluorescein isothiocyanate（Annexin PI）double staining with flow cytometry.Enzyme-linked Immunosorbnent assay method was used to detect the expression of IL-6 and Cx43 in PC3 cells. Results Below 25.00,50.00,100.00 μg/ml,Talidomide significantly inhibited the proliferation of PC3 cells in vitro,and the inhibition rate increased with the increase of time and concentration,the expression of IL-6 decreased with the increasing of concentration(r=-0.924，P=0.009),the expression of Cx43 had positive correlation with the concentration of thalidomide(r=0.915，P=0.010).Conclusion Thalidomide can inhibit the expression of IL-6 in PC3 cells,increase the expression levels of Cx43,restore the functional refreshment of gap junction intercellular communication function in prostate cancer PC3 cells for in inhibiting the proliferation of PC3 cells and inducing its apoptosis,in order to inhibit the growth of tumor.
尹卫华;夏红梅;罗小瑾;徐荣;胡小雄. 沙利度胺对前列腺癌PC3细胞的增殖及其IL-6和Cx43表达的影响[J]. 中国当代医药, 2017, 24(5): 8-11.
YIN Wei-hua;XIA Hong-mei;LUO Xiao-jin;XU Rong;HU Xiao-xiong. The effects of Thalidomide on the proliferation,IL-6 and Cx43 expression of prostate cancer PC3 cells. 中国当代医药, 2017, 24(5): 8-11.
Siegel RL，Miller KD，Jemal A.Cancer Statistics，2010[J].CA Cancer J Clin，2010，67（1）：7-30.
[2]
Detchokul S，Elangovan A，Edmund J，et al.Network analysis of an in vitro model of androgen-resistance in prostate cancer[J].BMC cancer，2015，60（2）：883-895.
Arlen PM，Gulley JL，Parker C，et al.A randomized phaseⅡstudy of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer[J]. Clin Cancer Res，2006，12（8）：1260-1269.
[7]
Chung TD，Yu JJ，Spiotto MT，et al.Characterization of the role of IL-6 in the progression of prostate cancer[J].Prostate，1999，38（3）：199-207.
[8]
Cohen T，Nahari D，Cerem LW，et al.Interleukin-6 induces the expression of vascular endothelial growth factor[J].J Biol Chem，1996，271（2）：736-741.
[9]
Habermann H，Bay V，Habermann W，et al.Alterations in gap junction protein expression in human benign prostatic byperplasia and prostate cancer[J].J Urol，2002，167（2）：655-660.
[10]
Fukushima M，Hattori Y，Yoshizawa T，et al.Combination of none-viral connexin 43 gene therapy and docetaxel inhibits the growth of human prostate cancer in mice[J].Int J Oncol，2007，30（1）：225-231.
[11]
Tate AW，Lung T，Radhakrishnan A，et al.Changes in gap junctional connexin isoforms during prostate cancer progression[J].Prostate，2006，66（1）：19-31.
[13]
Bao B，Ahmad A，Kong D，et al.Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF，IL6 and miRNAs that are attenuated by CDF[J].PLoS One，2012，7（8）：e43726.
[14]
Lee SO，Chun JY，Nadiminty N，et al.Interleukin 6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression[J].Prostate，2007，67（7）：764-73.
京公网安备 11010502046607号